Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7206323 | 0.69 | MEN1 (0.39) | ALDH1A1HPGDMAPTGLAACHE | |
| SCHEMBL10573026 | 0.67 | ALDH1A1 (0.54) | ALDH1A1HPGDMAPTGLAACHE | |
| SCHEMBL9572104 | 0.67 | ALDH1A1 (0.48) | ALDH1A1HPGDMAPTGLAACHE | |
| Acridine SCHEMBL3045498 | 0.66 | ALDH1A1 (1.00) | ALDH1A1HPGDMAPTGLAACHE | |
| Acridine SCHEMBL4972293 | 0.66 | ALDH1A1 (1.00) | ALDH1A1HPGDMAPTGLAACHE | |
| Acridine SCHEMBL1772714 | 0.66 | ALDH1A1 (1.00) | ALDH1A1HPGDMAPTGLAACHE | |
| Acridine SCHEMBL8339 | 0.66 | ALDH1A1 (1.00) | ALDH1A1HPGDMAPTGLAACHE | |
| Acridine SCHEMBL29352289 | 0.66 | ALDH1A1 (1.00) | ALDH1A1HPGDMAPTGLAACHE | |
| SCHEMBL28981243 | 0.65 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPTGLAACHE | |
| SCHEMBL5179394 | 0.65 | ALDH1A1 (0.46) | ALDH1A1HPGDMAPTGLAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210104679-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | LUMINESCENCE TECHNOLOGY CORPORATION (TW) | 2021-04-08 | — | — | US | claimed |
| US-20130065895-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-03-14 | — | — | US | claimed |
| EP-1483251-B1 | C3-CYANO EPOTHILONE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2009-12-23 | — | — | EP | claimed |
| WO-2008115531-A1 | PREVENTION AND TREATMENT OF INFECTIOUS CONDITIONS WITH ACTIVE VITAMIN D COMPOUNDS OR MIMICS THEREOF | NOVACEA, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080069814-A1 | Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof | NOVACEA, INC. | 2008-03-20 | — | — | US | claimed |
| WO-2008005560-A2 | PREVENTION OF THROMBOTIC DISORDERS WITH ACTIVE VITAMIN D COMPOUNDS | NOVACEA, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| US-20070037779-A1 | High dosage administered without inducing severe symptomatic hypercalcemia | NOVACEA, INC. | 2007-02-15 | — | — | US | claimed |
| EP-1483251-A4 | C3-CYANO EPOTHILONE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2006-02-08 | — | — | EP | claimed |
| EP-1483251-A1 | C3-CYANO EPOTHILONE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2004-12-08 | — | — | EP | claimed |
| US-6719540-B2 | 3-CYANO SUBSTITUTED MACROLIDE COMPOUNDS POSSESSING ANTI-TUMOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-13 | — | — | US | claimed |
| US-20030191089-A1 | C3-CYANO EPOTHILONE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-09 | — | — | US | claimed |
| US-20030186965-A1 | C12-cyano epothilone derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-02 | — | — | US | claimed |
| WO-2003077903-A1 | C12-CYANO EPOTHILONE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-25 | — | — | WO | claimed |
| WO-2003078411-A1 | C3-CYANO EPOTHILONE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-25 | — | — | WO | claimed |
| JP-1246263-A | — | — | None | — | — | JP | disclosed |
| WO-2024048435-A1 | RESIN COMPOSITION, CURED ARTICLE, LAMINATE, METHOD FOR PRODUCING CURED ARTICLE, METHOD FOR PRODUCING LAMINATE, METHOD FOR PRODUCING SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE | 富士フイルム株式会社 | 2024-03-07 | — | — | WO | disclosed |
| EP-3502159-B1 | COMPOSITION AND METHOD FOR THE DEPOSITION OF CONDUCTIVE POLYMERS ON DIELECTRIC SUBSTRATES | MACDERMID ENTHONE INC (US) | 2023-05-31 | — | — | EP | disclosed |
| US-5342865-A | Solvent system | THE DOW CHEMICAL COMPANY (US) | 1994-08-30 | — | — | US | disclosed |
| EP-0567248-A1 | Solvent system | THE DOW CHEMICAL COMPANY (US) | 1993-10-27 | — | — | EP | disclosed |
| JP-H01246263-A | QUINOLINE, QUINAZOLINE AND CINNOLINE BASED FUNGICIDES | ELI LILLY & CO | 1989-10-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080069814-A1 | Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof | CYP24A1, VDR, ADAMTS4 | ALDH1A1 1816/4885HPGD 161/4885MAPT 4801/4885 |
| US-20030186965-A1 | C12-cyano epothilone derivatives | CCNO, CCNT1, CCNA1 | ALDH1A1 1443/4885HPGD 152/4885MAPT 4467/4885 |
| US-20130065895-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRM4, GRIK4, GRIA4 | ALDH1A1 3879/4885HPGD 2200/4885MAPT 334/4885 |
| US-20070037779-A1 | High dosage administered without inducing severe symptomatic hypercalcemia | CYP24A1, VDR, PTH1R | ALDH1A1 2057/4885HPGD 83/4885MAPT 4811/4885 |
| US-20210104679-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | SLCO4C1, OR10J3, SLCO2B1 | ALDH1A1 931/4885HPGD 2931/4885MAPT 971/4885 |
| US-20030191089-A1 | C3-CYANO EPOTHILONE DERIVATIVES | HCCS, CCNO, CCNA1 | ALDH1A1 1236/4885HPGD 732/4885MAPT 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.